How Lewis was paid
$1.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Other | Total |
|---|---|---|---|---|---|
| Joel LewisChief Executive Officer & President | $624,000 | $312,000 | $182,763 | $56,019 | $1,174,782 |
| Khurram Jamil, M.D.Chief Medical Officer | $500,000 | $350,000 | $130,545 | $71,583 | $1,052,128 |
| Jack W. CallicuttChief Financial Officer | $400,000 | $220,000 | $130,545 | $56,019 | $806,564 |
What changed and why
- $1.2M$1,174,782 was CEO total compensation in 2025, down from $1,189,674 in 2024.
- $183K$182,763 was CEO stock compensation in 2025, down from $202,635 in 2024.
- $350K$350,000 was Dr. Jamil’s 2025 bonus, including a $200,000 retention bonus.
- $220K$220,000 was Mr. Callicutt’s 2025 bonus, including a $100,000 retention bonus.
- 96%96% of votes cast favored NEO compensation at the 2025 annual meeting.
Other Galectin Therapeutics proxy statements
- 2025 proxy statement
Joel Lewis paid $1.2M (+23% on the year).
Filed Oct 22, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.